Vericel Corporation (NASDAQ: VCEL) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Vericel Corporation to similar businesses based on the strength of its institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Risk and Volatility
Vericel Corporation has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500. Comparatively, Vericel Corporation’s competitors have a beta of 1.28, indicating that their average share price is 28% more volatile than the S&P 500.
This table compares Vericel Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vericel Corporation Competitors||-13,404.97%||246.04%||-20.09%|
Institutional and Insider Ownership
33.8% of Vericel Corporation shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 3.3% of Vericel Corporation shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Vericel Corporation and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vericel Corporation||$53.77 million||-$20.03 million||-4.18|
|Vericel Corporation Competitors||$579.30 million||$241.72 million||-6.62|
Vericel Corporation’s competitors have higher revenue and earnings than Vericel Corporation. Vericel Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and target prices for Vericel Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vericel Corporation Competitors||116||750||1613||58||2.64|
Vericel Corporation currently has a consensus price target of $6.33, indicating a potential upside of 37.68%. As a group, “Biopharmaceuticals” companies have a potential upside of 5.03%. Given Vericel Corporation’s stronger consensus rating and higher possible upside, research analysts plainly believe Vericel Corporation is more favorable than its competitors.
Vericel Corporation competitors beat Vericel Corporation on 7 of the 12 factors compared.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.